Work

Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: 12-Month Results from the Phase 3 APPEAR-C3G Study

Year: 2024

Type: article

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.2024f5gka890

Authors: Carla M. Nester, Richard J. Smith, David Kavanagh, Marina Vivarelli, Giuseppe Remuzzi, Ming-Hui Zhao, Edwin Kwan Soon Wong, Yaqin Wang, Angelo J. Trapani, Induja Krishnan, Nicholas J. Webb, Matthias Meier, Andrew S. Bomback

Institutions: University of Iowa Stead Family Children’s Hospital, University of Iowa, Royal Victoria Infirmary, Newcastle University, Bambino Gesù Children's Hospital, Mario Negri Institute for Pharmacological Research, Peking Union Medical College Hospital, Novartis (Switzerland), Columbia University

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403834474

FWCI: 1.678

Cites:

Cited by: 10

Related to: 10